TY  - JOUR
PY  - 2007//
TI  - Therapeutic vaccine for melanoma: The untouched grail?
JO  - Expert review of vaccines
A1  - Ding, Z.
A1  - Wei, Y.
SP  - 907
EP  - 911
VL  - 6
IS  - 6
N2  - Malignant melanoma remains the most lethal form of cancer, especially for those with lymph node involvement or metastases. Owing to its intrinsic nature of highly resistance to conventional chemotherapy and radiotherapy, advanced melanoma was considered by most to be indolent, defying any tempts to cure. For decades, there had been studies on the adjuvant treatment in order to lower recurrence rate and to improve the likelihood of response. Clinical trials are currently ongoing to explore the role of specific active immunotherapy (vaccine) in the treatment of patients with high risk of recurrence and metastasis. The current paper under evaluation described one randomized Phase III trial of the therapeutic vaccine Melacine® plus low-dose IFN-α2b, which had an effect comparable to standard high-dose interferon-α2b but with less toxicity. © 2007 Future Drugs Ltd.<p /> <p>Language: en</p>
LA  - en
SN  - 1476-0584
UR  - http://dx.doi.org/10.1586/14760584.6.6.907
ID  - ref1
ER  -